Background about COVID-19 {#s0005}
=========================

In December 2019, the world health organization (WHO) had reported a sudden elevation in the incidence of pneumonia in Wuhan city, China without a known relevant cause [@b0005]. These raised levels in pneumonia cases were then attributed to the newly diagnosed coronavirus disease (COVID-19) which is caused by a highly contagious virus, that consequently resulted in a global pandemic infection in a relatively short duration [@b0010]. COVID-19 can affect people both physically and mentally. WHO had announced that mental symptoms had aroused due to the public fear [@b0015]. Studies had suggested that stress, anxiety and depression would be associated with COVID-19 infection [@b0020], [@b0025].

The symptoms of COVID-19 had shown to range from mild or asymptomatic to severe. Most infected subjects had shown mild to moderate breathing problems and recover without vigorous treatment interventions. The severity of COVID-19 depends largely on the immunity and the release of inflammatory mediators [@b0030].

Critically ill patients had shown symptoms of either mild or severe cytokine storms due to over activity of the immune system which is a major cause of death. This cytokine storm releases different inflammatory mediators, mainly IL-6 [@b0065].

Early data regarding the current COVID-19 pandemic suggests that 60% of patients admitted to the intensive care unit (ICU) required mechanical ventilation, and the acute respiratory destress syndrome (ARDS) associated with pneumonia was diagnosed in about 40% of patients treated in the ICU [@b0035]. Moreover, studies of COVID-19 had reported that pneumonia and ARDS are a consequence of coagulopathy and pulmonary embolus [@b0040], [@b0045]. If ARDS could be prevented or mitigated, we can expect a significant reduction in COVID-19 associated mortality [@b0050].

People of all ages may have an increased risk of serious illnesses and unfortunately, till now, there is no available vaccine to protect against COVID-19 and no definitive and effective radical treatment for COVID-19. Therefore, Ministry of health in the affected countries had advised their civils to protect their selves from exposure to the infected subjects [@b0055], [@b0060].

Stress associated with COVID-19 {#s0010}
===============================

The pandemic of COVID-19 has shown to affect people physically and psychologically [@b0065]. The associated stress, anxiety and depression had shown to be responsible for a part in the pathogenesis of COVID-19 [@b0070], [@b0075]. Stress is defined as the process by which environmental requirements transform the organism\'s adaptability, leading to psychological and biological changes [@b0070]. Clinical evidences have proved an association between specific mood disorders, caused by sustained or chronic stress and the immune dysregulation [@b0075], [@b0080], [@b0085].

A study conducted on COVID-19 patients had reported that the severe cases are caused by a malfunction or deficiency in the immune system [@b0090]. Immune dysregulation is a consequence of elevation of cortisol, the stress hormone, and reduction of serotonin [@b0095]. This hormonal dysregulation might promote the initiation and progression of the infection [@b0100].

In addition, stressful conditions associated with infection had shown to cause an elevation in the levels of the inflammatory mediator IL-6 that causes a decrease in the number and activity of cytotoxic T-cells and natural killer (NK) cells [@b0105], [@b0110]. Moreover, the resulted depression due to prolonged stress was found to be associated with higher levels of serum IL-6 and tumor necrosis factor- alfa (TNF-α) [@b0110], catecholamines, inhibitory T cells and histamine [@b0070]. The decreased counts of lymphocytes, monocytes, eosinophils and basophils associated with depression had shown to participate more in suppressing the immune response [@b0115], [@b0120].

These elevated inflammatory cytokines had shown also to precipitate depression and inflammations to many organs especially lung which is a serious condition and a main cause of mortality in COVID-19.

Serotonin role in regulating immunity and resistance to infection {#s0015}
=================================================================

Serotonin (5-HT) is a neurotransmitter and immunomodulator. It improves the mood and it is also responsible for feeling of happiness and calmness. 5-HT was found to regulate innate and adaptive immune responses. In addition, it has shown to play important roles in brain function, hemostasis, sleeping, mood regulation, behaviors and phycological state. It also has important roles in many different peripheral tissues, central nervous system (CNS) and immune cells [@b0125], [@b0130]. The decrease in 5-HT levels is a major cause of depression like symptoms [@b0135]

Pathological and physiological conditions may affect the role of serotonin in properly regulating the immune response [@b0140]. Many researches had concluded that elevated serotonin levels plays a vital role in immunity against viral infections [@b0145], [@b0150]. On the other hand, lowered levels of 5-HT had shown a correlation with susceptibility to bacterial infections [@b0135].

COVID-19 had shown to increase the levels of pro-inflammatory cytokines [@b0155]. These elevated levels had shown to increase the rate of metabolism of serotonin due to activation of indoleamine-2,3-dioxygenase (IDO) enzyme that metabolizes tryptophan which is the precursor of serotonin [@b0160]. Moreover, studies had reported that the elevated levels of C-reactive protein (CRP) had shown to be linked to depression like symptoms [@b0165], [@b0170], [@b0175].

Statement of hypothesis {#s0020}
=======================

Generally, antidepressants are found to augment the immune system response through inhibiting pro-inflammatory factors, in particular CRP, TNF-α, IL-1β and IL-6 [@b0180]. Selective serotonin reuptake inhibitors (SSRIs) are used as antidepressants and anxiolytics by manipulating serotonin within the brain. SSRIs increase serotonin via proscribing its reuptake into the presynaptic cell then increasing the level of serotonin inside the synaptic cleft to bind the postsynaptic receptor [@b0185].

SSRIs have shown an effective role in relieving symptoms of stress and anxiety, which enhances the role of immunity in confronting infection. This class had proved to prevent the elevation in cytokine levels which causes depression [@b0190], [@b0195], [@b0200], [@b0205]. Moreover, SSRIs use had resulted in lowering endotoxin-induced fatigue [@b0195]. *In vitro* antibacterial effect and modulation of antibiotic activity were also associated with using SSRIs [@b0210], [@b0215], [@b0220].

In COVID-19 patients, SSRIs may help in hindering cytokine release syndrome that is responsible for aggravating sickness progression and the subsequent increase in TNFα [@b0225]. A study had reported the effective role of SSRIs in severe chronic obstructive pulmonary disease where a significant increase of patients' oxygen saturation was observed [@b0230].

Therefore, SSRIs family may help in controlling symptoms of COVID-19 patients due to its reported potent anti-inflammatory activity in different inflammatory disorders [@b0195], [@b0235]

Antioxidant and anticoagulant properties of SSRIs {#s0025}
=================================================

Many researches had reported the high therapeutic efficacy of SSRIs *via* reversal of the oxidative damage by the protective enhancement of antioxidant status following a stress-induced decline [@b0240]. It has shown a significant inhibitory effect on nitric oxide (NO) production in a dose-dependent manner [@b0245]. As a consequence, SSRIs had shown anti-inflammatory and analgesic properties [@b0250].

SSRIs have shown anticoagulant properties [@b0255] making it a promising option for COVID-19 patients who mostly experience venous and arterial thrombosis that is the major cause of mortality.

Antiviral properties of SSRIs {#s0030}
=============================

Given the high replicative potential of COVID-19, it is possible that the very high viral burden in the lung leads to a large inflammatory response which is fatal. Fortunately, SSRI was found to have antiviral effects beside being a mood stabilizer. A patent study had reported the efficiency of SSRIs treatment in reducing chemokine and cytokine expression in the infected cells and hence, it has a role in combating infections [@b0260]. SSRIs had shown to potentiate the antiviral potency of certain antivirals [@b0265]. SSRIs had reported HIV receptor and coreceptor downregulation [@b0270], Ebola virus lowered activity [@b0275] and reduced viral replication of Coxsackievirus B4 [@b0280] by their use beside the antiviral.

Which SSRI are we going to use and why? {#s0035}
=======================================

Sertraline is a member of SSRIs that is deeply suggested as a favorable therapeutic choice for COVID-19 patients because it has a wide therapeutic index and minimal anticholinergic activity which make it a safe option for elderly patients or those with underlying cardiovascular disorders [@b0285].

Sertraline had strong anti-inflammatory effects via decreasing and regulating of pro-inflammatory cytokines [@b0290], [@b0295]. It had significantly increased the activity of antibiotics with some resistant strains of *S. aureus, E. Coli* and *P. aeruginosa*. Thus, sertraline is a resistance modifying agent when used in combination with the antibiotics [@b0220].

Also sertraline had reported antiviral efficacy [@b0300] when used effectively in reducing influenza-induced lung inflammation and lowering mortality rate when combined with oseltamivir in a mouse model [@b0265].

Regarding the ideal timing of starting sertraline, it would be advisable to start once respiratory symptom began to be worse or, in other words, before the onset of acute lung injury which precedes the occurrence of the fatal pneumonia.

Conclusions {#s0040}
===========

In this hypothesis, we needed to raise the effective role of serotonin in the activation of T-cells and enhancement of the immune system in COVID-19 patients. This may show a high usefulness for the vulnerable subjects and medical staff who are constantly exposed to fatigue, stress, anxiety and depression caused by COVID-19 pandemic and had shown to destroy the immunity against any viral attack.

SSRI would play important roles in COVID-19 infection via treating anxiety and stress, and increasing the number and function of immune cells. Cytokine release syndrome in COVID-19 is expected to be ameliorated by the use of sertraline that lower IL-6 and IL-10 levels. Moreover, we suggest that sertraline may exhibit antiviral effect against COVID-19 but with unknown mechanism of action. We think that understanding the mechanism of halting the viral replication would be an important research area that might benefit the scientific field.

We advise giving sertraline to moderate cases of COVID- 19 patients as a prophylaxis against lethal pulmonary symptoms and it should be used as an adjuvant therapy to drugs used in the protocol of COVID-19 treatment.

This research hypothesis would provide a great benefit in fastening the recovery and reducing mortality rates in COVID-19 patients. Moreover, if using sertraline is found to be effective in preventing the associated ARDS, its global use would be highly beneficial to the humanity. Besides, it is safe, tolerable and highly affordable.
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